Cita APA (7a ed.)
Hua, X., Church, K., Walker, W., L'Hostis, P., Viardot, G., Danjou, P., . . . Moebius, H. J. (2022). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial. Journal of Alzheimer's Disease, 86(3), 1399-1414.
Cita Chicago Style (17a ed.)
Hua, Xue, Kevin Church, William Walker, Philippe L'Hostis, Geoffrey Viardot, Philippe Danjou, Suzanne Hendrix, y Hans J. Moebius. "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial." Journal of Alzheimer's Disease 86, no. 3 (2022): 1399-1414.
Cita MLA (9a ed.)
Hua, Xue, et al. "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial." Journal of Alzheimer's Disease, vol. 86, no. 3, 2022, pp. 1399-1414.
Precaución: Estas citas no son 100% exactas.